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ABSTRACT: As a new class of antidiabetic drug, incretin-based therapies, which include dipeptidyl peptidase-4 
inhibitors (DPP-4Is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), have raised concerns about 
symptoms of withdrawal in patients with type 2 diabetes mellitus (T2DM), such as dizziness and headache. To 
systematically evaluate whether incretin-based therapies may lead to dizziness and headache in patients with 
T2DM compared to other traditional antidiabetic drugs or placebo. We searched Medline, Embase, the Cochrane 
library, and clinicaltrials.gov from inception through June 23, 2017, to identify randomized controlled trials of 
the safety of DPP-4Is or GLP-1 RAs versus placebo or other antidiabetic drugs in T2DM patients. We used the 
network meta-analysis under the frequentist framework to compare the association between multiple antidiabetic 
drugs and dizziness and headache. A total of 233 clinical trials with nine treatments and 147,710 patients were 
included: two incretin-based therapies, one placebo, and six traditional antidiabetic drugs (metformin, insulin, 
sulfonylurea, thiazolidinediones, alpha-glucosidase inhibitor, and sodium-glucose co-transporter 2). Compared 
to insulin, thiazolidinediones, or placebo, GLP-1 RAs statistically significantly increased the risk of dizziness 
(odds ratios [ORs]: 1.92, 1.57, and 1.40, respectively) and headache (ORs: 1.34, 1.41, and 1.18, respectively). DPP-
4Is increased the risk of headache (OR: 1.22, 95% confidence interval [CI]: 1.02 to 1.46; moderate quality) and 
dizziness (OR: 1.46, 95% CI: 1.05 to 2.03; moderate quality) compared to insulin. Of the incretin-based therapies, 
DPP-4Is had a lower risk of dizziness than GLP-1 RAs (OR: 0.76, 95% CI: 0.67 to 0.87; high quality). Ranking 
probability analysis indicated that GLP-1 RAs may have the greatest risk of both dizziness and headache among 
the nine treatments (22.5% and 23.4%, respectively), whereas DPP-4Is were in the middle (46.2% and 45.0%, 
respectively). Incretin-based therapies increase the risk of dizziness and headache compared to insulin, 
thiazolidinediones, and placebo. 
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Patient compliance with taking antidiabetic agents ranges 
from about 40% to 60% [1–3]; one study even found a 
maximal adherence rate of only 1% [4]. Many factors are 
related to poor compliance, including patient knowledge, 
patient beliefs, drug type, and drug side effects; of these 
factors, side effects contribute most to nonadherence [5]. 
Poor compliance may result in inadequate control of 
blood glucose. 
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) and 
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) 
are incretin-based therapies, a new class of antidiabetic 
treatment. GLP-1 RAs are receptors of GLP-1, an incretin 
that can decrease blood sugar levels by enhancing the 
secretion of insulin [6, 7]. Because GLP-1 can be rapidly 
degraded by DPP-4 with a half-life of about 2 min, DPP-
4Is can increase GLP-1 activity [6, 8, 9]. Although some 
of the benefits of this novel class of antidiabetic drugs 
including insulinotropic effects, low rates of 
hypoglycemia, no weight gain and improvement in β-cell 
function have been studied, compliance rates are 
unsatisfactory [10, 11]. The increasing popularity of 
incretin-based therapies in recent years has raised more 
and more concerns about safety [8, 12–14]. Multiple 
clinical trials have shown that incretin-based therapies 
may harm the central nervous system [9, 15]. Frequent 
dizziness and headache, symptoms of diabetes itself [16–
19], may reduce patients’ compliance and worsen their 
glycemic control. These safety issues motivated the 
present study.  
The objective of our network meta-analysis (NMA) 
was to evaluate the neurological safety of incretin-based 
therapies versus traditional antidiabetic drugs or placebo, 
particularly in terms of dizziness and headache, in patients 
with type 2 diabetes mellitus (T2DM) to enable 
practitioners to better manage adverse events to improve 
blood glucose control.  
To date, five DPP-4Is (sitagliptin, vildagliptin, 
saxagliptin, linagliptin, and alogliptin) and five GLP-1 
RAs (exenatide, liraglutide, albiglutide, lixisenatide, and 
dulaglutide) have been approved for use in health care 
[20]. 
 
MATERIALS AND METHODS 
 
This study was registered with the International 
Prospective Register of Systematic Reviews (CRD420 
18091035). We reported this NMA according to the 
PRISMA for Network Meta-Analyses. 
 
Data sources and searches 
 
Medline, Embase, the Cochrane Library, and 
clinicaltrials.gov were searched from inception through 
June 23, 2017, to identify both published and unpublished 
trials. We searched the databases using glp-1 receptor 
agonists and dpp-4 inhibitors as keywords or mesh terms 
accompanied by relevant free words. Example of the 
search strategy in Embase is provided in Supplementary 
Table 1. 
 
Eligibility criteria 
 
We included only randomized controlled trials (either 
open-label, single-blind, double-blind, triple-blind, or 
quadruple-blind trials) published in English with available 
data on relevant outcomes in which incretin-based 
therapies and placebo or other antidiabetic drugs were 
compared. The adverse events included dizziness and 
headache, both from secondary outcomes.  
 
Study selection 
 
All titles and abstracts were examined for inclusion by one 
senior reviewer (FS). Works that clearly did not meet the 
inclusion criteria (e.g., no T2DM, use of the same 
incretin-based therapies in both arms) were excluded. 
Then the full texts of all remaining articles were examined 
by two reviewers (LG and JY). Disagreements were 
resolved through discussion between the two independent 
reviewers or by the senior investigator (FS). 
 
Data extraction and quality assessment  
 
ADDIS 1.16.5 was used to manage information extracted 
from trials, including study characteristics (author, 
publication year, duration of follow-up), participant 
details (age, sex, baseline treatment, duration of T2DM, 
baseline HbA1c), and reported outcomes in the 
experimental and control groups (number of events of 
dizziness and headache). Data extraction was performed 
by four investigators (LG, JY, SW, SY) independently 
and checked at random by one reviewer (LG). The risk of 
bias in each included study was independently assessed 
by one reviewer (LG) and then checked by another 
reviewer (SW) using the Cochrane Risk of Bias tool [21]. 
In addition, we used the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) 
framework to assess the quality of each mixed comparison 
and the total ranking of treatments [21, 22].  
 
Data analysis 
 
Direct comparison: We calculated pooled odds ratios 
(ORs) and 95% confidence intervals (95% CIs) of events 
of dizziness and headache using the random-effects model 
in STATA 13.1. I2 was used to describe the heterogeneity 
between pairwise comparisons. We included only double-
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blind, triple-blind, and quadruple-blind trials in the 
sensitivity analysis. 
Indirect and mixed comparison: We used the 
frequentist framework to perform random-effects NMA. 
Pooled ORs and 95% CIs were also summarized. Next, 
we estimated the ranking probabilities of each treatment 
and then ranked the drugs using surface under the 
cumulative ranking curves. This procedure gives a 
percentage, interpreted as the probability of a treatment 
being the most effective without uncertainty on dizziness 
or headache events; 100% means that the treatment is 
certain to be the best and 0% means it is certain to be the 
worst. We also used the contribution plot to measure the 
percent contribution of each direct comparison to the 
mixed estimates, the indirect estimates, and the entire 
network. To assess publication bias, we used the 
comparison-adjusted funnel plot to detect the effects of 
small studies. Finally, we performed subgroup analysis 
(by age group, duration of T2DM, HbA1c% level, trial 
duration, sample size, and sponsorship), sensitivity 
analysis (excluding open-label trials), as well as 
univariate and multivariate meta-regression (by age, body 
mass index, HbA1c%, and duration of T2DM). All of 
these analyses were performed in STATA 13.1.  
 
Examination of assumptions in the NMA 
 
To check the consistency of the NMA, we used the node-
splitting model [23] to assess the inconsistency between 
direct and indirect treatment effects. Then we used the 
loop-specific approach to identify all triangular or 
quadrilateral loops in the network and estimate the 
respective inconsistency factors and their uncertainty 
[24]. As for heterogeneity, the predictive interval plot was 
used to estimate effect sizes and their uncertainty for all 
comparisons. In addition, the R 3.3.3 netmeta package 
was used to calculate the global I2 statistic. 
 
 
 
 
 
 
Figure 1. Flow chart of studies considered for inclusion. 
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RESULTS 
 
Characteristics of the studies 
 
A total of 233 trials with 147,710 participants met the 
inclusion criteria, of which 141 trials reported dizziness 
and 209 trials reported headache (Supplementary Table 
2). These trials were published between 2004 and 2017, 
and the median trial duration was 26 weeks. Participants’ 
mean age was 56.32 years, the mean baseline HbA1c was 
8.18%, and the median duration of T2DM was 6.4 years. 
Fig. 1 shows the flowchart of trial selection. The trials 
analyzed nine treatments: two incretin-based therapies (10 
different DPP-4Is and 8 different GLP-1 RAs), placebo, 
and six traditional antidiabetic drugs (metformin, insulin, 
sulfonylurea, thiazolidinediones [TZD], alpha-
glucosidase inhibitor, and sodium-glucose co-transporter 
2). The network plots are shown in Supplementary Fig. 1. 
A total of 128 trials referred to DPP-4Is, 93 to GLP-RAs, 
and 12 to both DPP-4Is and GLP-RAs. Most of trials 
(95.3%) were two-arm studies, the other were three-arm 
(3.8%) and four-arm (0.9%) studies. 
 
Results of pairwise meta-analysis 
 
Fig. 2 shows the associations between incretin-based 
therapies and other active antidiabetic drugs and dizziness 
and headache according to pairwise meta-analysis. As for 
dizziness, DPP-4Is reduced the risk of dizziness versus 
sulfonylurea. Although DPP-4Is had a statistically 
significant effect compared to sodium-glucose co-
transporter 2, the CI was broad because of the small 
sample size. Compared to insulin and placebo, GLP-1 
RAs increased the risk of dizziness, with ORs of 2.06 and 
1.39. As for headache, DPP-4Is increased the risk of 
headache compared to TZD. GLP-1 RAs had a more 
harmful effect than insulin and placebo. In contrast, 
compared to metformin, GLP-1 RAs had a protective 
effect, with an OR of 0.61.  
 
Results of the NMA 
 
Results of the NMA are shown in Fig. 2. As for dizziness, 
the mixed effect was statistically significant for GLP-1 
RAs versus insulin, TZD, and placebo with ORs of 1.92, 
1.57 and 1.40, respectively. Meanwhile, DPP-4Is had a 
more harmful effect than insulin (OR=1.46, 95% CI: 1.05, 
2.03). However, compared to sulfonylurea, DPP-4Is and 
GLP-1 RAs had a protective effect, with ORs of 0.54 and 
0.71. In addition, DPP-4Is had a lower risk of dizziness 
than GLP-1 RAs (OR: 0.76, 95% CI: 0.67, 0.87). As for 
headache, DPP-4Is increased the risk of headache 
compared to insulin, TZD, and placebo (OR=1.22, 1.29 
and 1.08, respectively). GLP-1 RAs had a similar effect, 
with ORs ranging from 1.18 to 1.41. Fig. 3 visually shows 
two-dimensional graphs for dizziness and headache in 
NMA and direct comparisons. 
Supplementary Table 3 shows the ranking probability 
of the safety in terms of dizziness and headache. DPP-4Is 
ranked in the middle (ranked fifth for both dizziness and 
headache) and GLP-1 RAs ranked lower (ranked eighth 
for dizziness, ninth for headache) among the nine 
antidiabetic drugs, so did the comprehensive rankings of 
these two treatments in total safety for these symptoms. 
According to the contribution plot for the incretin-based 
regimens network of dizziness and headache (Supple-
mentary Fig. 2), DPP-4Is and GLP-1 RAs versus placebo 
contributed the most. 
 
Methodological quality and risk of bias 
 
Supplementary Fig. 3 presents the methodological quality 
of different outcomes. Of the total 233 studies included in 
our analysis, the large majority reported the use of random 
sequence generation (94.4%), allocation concealment 
(81.9%), blinding of participants and personnel (80.2%), 
blinding of outcome assessment (77.6%), complete 
outcome data (94.8%), and selective reporting (91.8%). In 
addition, only 5.2% of the trials were conducted by 
research institutions. 
According to visual inspection of the funnel plot, 
publication bias was found for dizziness. In contrast, the 
funnel plot for headache was quite symmetric, which 
suggested no publication bias (Supplementary Fig. 4). 
GRADE showed that the ranking of treatments ranged 
from very low to high, and for both headache and 
dizziness most comparisons were rated high or moderate 
(Supplementary Table 4). 
 
Results of assumptions in the NMA  
 
Evaluation of the local inconsistency of dizziness and 
headache showed that most loops were consistent 
according to the CIs (Supplementary Fig. 5). Evaluation 
of the inconsistency by the node-splitting model did not 
reveal any significant difference in dizziness between 
direct and indirect comparisons, and only two 
comparisons (DPP-4Is vs. metformin and GLP-1 RAs vs. 
metformin) showed a significant difference for headache 
(Supplementary Table 5). This may have been because of 
different values for baseline HbA1c. The mixed 
comparison of DPP-4Is versus metformin came mainly 
from direct comparisons of DPP-4Is versus metformin 
and GLP-1 RAs versus metformin, as did the mixed 
comparison of GLP-1 RAs versus metformin. Moreover, 
from the distribution of several baseline factors, including 
age, body mass index, duration of T2DM, and HbA1c, we 
could see that baseline HbA1c differed significantly, 
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which may have affected the transitivity of the results 
(Supplementary Fig. 6). It was also demonstrated in the 
subgroup analysis (Supplementary Table 6). In addition, 
the duration of T2DM and trial duration are likely other 
reasons for some of the inconsistency between direct and 
indirect comparisons (Supplementary Table 6). 
Predictive intervals indicated that no comparisons 
were affected by estimated heterogeneity for dizziness, 
and 8.3% of the comparisons related to concerned drugs 
for headache had been slightly affected (Supplementary 
Fig. 7), which may be due to the difference of some 
baseline characteristics (Supplementary Table 7) and 
study design (Supplementary Fig. 8). 
Testing for global inconsistency did not reveal any 
significant difference between consistency and 
inconsistency models (P=0.285 for dizziness and P=0.216 
for headache). The global I2 was 0% (dizziness) and 6.7% 
(headache).  
 
 
 
 
Figure 2. Odds ratios (ORs) with 95%CIs of NMA. For dizziness (A) and headache (B), results of direct comparisons were 
listed in the upper triangle, and the estimation was calculated as the row-defining treatment compared with the column-defining 
treatment. Results of NMA were listed in the lower triangle, the estimation was calculated as the column-defining treatment 
compared with the row-defining treatment. The statistically significant results were bolded in red. NA: not available. DPP-4Is: 
dipeptidyl peptidase-4 inhibitors; GLP-1 RAs: glucagon-like peptide-1 receptor agonists; SGLT-2: sodium-glucose co-transporter 
2; TZD: thiazolidinediones; AGI: alpha-glucosidase inhibitor. 
 
Results of other analyses 
 
Subgroup analysis: According to the subgroup NMA, 
compared to placebo, GLP-1 RAs had a more harmful 
effect on dizziness in patients with T2DM duration ≥ 5 
years, mean HbA1c ≥ 7.5%, and trial duration ≤ 24 
weeks. The results were roughly similar for headache 
(Supplementary Table 8).  
Sensitivity analysis: Results of the sensitivity NMA with 
double-blind, triple-blind, and quadruple-blind studies 
only were generally consistent with previous studies for 
dizziness (Supplementary Fig. 9). For headache, results 
for GLP-1 RAs versus TZD and placebo were in line with 
previous studies, whereas other comparisons that included 
incretin-based therapies did not differ significantly.  
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Figure 3. Two-dimensional graphs about risk on dizziness and headache. ORs in comparison with placebo (reference) of NMA 
(A) and direct comparisons (B) were used. Error bars are 95% CIs. Different drugs are represented by diﬀerent colored nodes. 
Metformin and AGI were not included in direct comparisons because no trials focus on these drugs compared with placebo. DPP-4Is: 
dipeptidyl peptidase-4 inhibitors; GLP-1 RAs: glucagon-like peptide-1 receptor agonists; SGLT-2: sodium-glucose co-transporter 2; 
TZD: thiazolidinediones; AGI: alpha-glucosidase inhibitor. 
 
Meta-regression: Univariate meta-regression showed that 
for headache, the pooled OR of DPP-4Is decreased by 
0.96 for every 1-year change in duration of T2DM 
compared to placebo. Multivariate meta-regression 
showed similar results (Supplementary Table 9). 
 
DISCUSSION  
 
With the increasing use of DPP-4Is and GLP-1 RAs, more 
and more people have begun to be concerned about the 
safety of these treatments. In recent years, there have been 
systematic reviews of the cardiovascular effects of 
incretin-based therapies [13, 25] and their risks of bone 
fractures [26, 27], respiratory tract infections [28], and 
pancreatic cancer [29]. Although some studies have 
reported dizziness and headache after taking DPP-4Is or 
GLP-1 RAs, these symptoms have usually been 
considered secondary outcomes and have not been taken 
seriously by doctors. In addition, we found two large 
cohort studies with sample sizes of more than 1,000, GLP-
1 RAs were associated with a higher risk of dizziness than 
DPP-4Is [30]. Moreover, DPP-4Is increased the risk of 
dizziness compared to placebo [31]. To date there have 
been no systematic reviews of dizziness and headache 
after incretin-based therapies.  
There are two potential mechanisms through which 
incretin-based therapies result in dizziness and headache. 
The first has to do with the impact on blood flow. Studies 
have shown that postprandial GLP-1 increases regional 
cerebral blood flow [32]. Moreover, population-based 
studies [33–37] have shown that GLP-1 RAs and DPP-4Is 
might have a role in reducing blood pressure, which may 
cause dizziness (see www.mayoclinic.org/diseases-
conditions/dizziness/symptoms-causes/syc-20371787).   
In addition, the dilation of cerebral blood vessels 
caused by lower blood pressure and increased regional 
cerebral blood flow may stretch surrounding nerves, 
causing them to send signals to the trigeminal system, 
which may cause headache (see www.scientificamerican. 
com/article/what-causes-headaches/). The second 
mechanism relates to the impact on neurological 
functions. Although GLP-1 RAs and DPP-4Is function 
differently, their ultimate purpose is the same: to extend 
the half-life of GLP-1 and increase its activity. GLP-1 
RAs may act on the brain by passing through the blood-
brain barrier as well as interacting with vagal afferent 
nerves [38]. DPP-4Is can block the enzyme DPP-4 and 
thereby increase levels of incretin. Similarly, GLP-1 
influences various brain functions by interacting with 
afferent nerves of the autonomic nervous system, which 
distributes GLP-1 receptors [39–41]. Activation of certain 
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areas of the human brain may cause these symptoms. 
However, more studies are needed to determine the exact 
relation between the agent and this kind of neurological 
manifestation. 
As symptoms that affect the nervous system, 
headache and dizziness may have adverse impacts on the 
feelings, work, and lives of patients who take certain 
drugs and thereby may reduce compliance with a 
medication regimen. For example, a systematic review of 
patients with headache [42] showed that adherence rates 
range from 25% to 94%; this may affect disease control. 
Currently no clinical guidelines recommend how to deal 
with such symptoms and whether to change medication or 
reduce the dose. 
The major advantage of our study is the use of NMA 
with high-quality studies to compare adverse events of 
dizziness and headache caused by incretin-based therapies 
and other antidiabetic drugs and placebo. Moreover, 
GRADE showed that the majority of the results were of 
high or moderate quality. Nevertheless, some limitations 
should be noted. Different studies had different standards 
for judging dizziness and headache. Investigators could 
only obtain subjective data reported by patients, which 
may have led to great uncertainty. Moreover, few studies 
indicated whether these symptoms affected patients’ 
compliance, extra medical burden, lifestyle, or 
psychological status. Another limitation is that the 
subgroup analysis and regression were based on the 
average result of each trial, which may not have 
accurately reflected every participant. Thus, readers 
should be cautious when using the results of this study to 
guide clinical practice.  
 
Conclusions  
 
Incretin-based therapies increase the risk of dizziness and 
headache compared to insulin, TZD, and placebo, a fact 
that should be emphasized by physicians. Future 
guidelines should pay more attention to these therapies. 
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